Abstract: The present invention relates to a medium composition for preparing an intestinal organoid. In addition, the present invention relates to: a method for preparing an intestinal organoid, comprising a step of culturing using the medium composition; and an intestinal organoid prepared by the preparation method. The medium for preparing an intestinal organoid can promote the proliferation of the intestinal organoid and maintain the stemness of the intestinal organoid. Therefore, the medium can be used in preparing a large amount of intestinal organoids of excellent quality, and intestinal organoids prepared using the medium can be used as agents for preventing or treating intestine-associated diseases, alternatives to animal experimental models of intestine-associated diseases, and the like.

Abstract: The present disclosure relates to a blood-brain barrier permeable fusion protein and uses thereof, and provides a blood-brain barrier permeable fusion protein, a polynucleotide encoding the fusion protein, a vector including the polynucleotide, a transfection cell line transfected with the vector, and a pharmaceutical composition for preventing or treating diseases associated with brain dysfunction, including the fusion protein as an active ingredient.

Abstract: A method for preparing an oral composite tablet containing a proton pump inhibitor and an antacid and an oral composite tablet prepared by the method are disclosed. The method prepare an oral composite tablet with excellent appearance stability and high productivity. The proton pump inhibitor includes esomeprazole, omeprazole, lansoprazole, rabeprazole, pantoprazole, or combinations thereof.

Abstract: An oral dosage form in a form of a bi-layer complex tablet is disclosed. The bi-layer oral complex tablet contains colloidal silicon dioxide in an amount of 0.5 to 2% by weight based on a total weight of the first layer. A method for manufacturing the bi-layer oral complex tablet dosage form is also disclosed.

Abstract: A battery module includes a module housing with a simplified assembling process and an improved energy density. The battery module includes a battery assembly configured to include a plurality of secondary batteries and has front, rear, upper, lower, left and right sides; and a module housing including a first frame located at the left side of the battery assembly and having a plate shape with opposing ends bent rightward so that bent portions thereof are respectively located at the upper side and the lower side of the battery assembly, and a second frame located at the right side of the battery assembly and having a plate shape with opposing ends bent leftward so that bent portions thereof are respectively located at the upper side and the lower side of the battery assembly and are coupled with the bent portions of the first frame, respectively.

Abstract: A method for detecting a foreign object disposed in a charging area of a wireless power transmitter, the method including transmitting, by a wireless power receiver to the wireless power transmitter, a foreign object detection status packet including a mode bit field indicating whether the foreign object detection status packet includes a reference peak frequency of the wireless power receiver; and receiving, by the wireless power receiver from the wireless power transmitter, a response indicating the foreign object is present or not present in the charging area, wherein a data packet is used for information exchange between the wireless power transmitter and the wireless power receiver, wherein the reference peak frequency is pre-assigned to the wireless power receiver, wherein the response is determined based on a comparison of a measured peak frequency of a power signal transmitted by the wireless power transmitter and an adaptable threshold frequency adapted based on the reference peak frequency included

Abstract: The present disclosure relates to a battery, and more particularly to a battery electrode. According to some implementations of the present disclosure, a method for manufacturing a battery electrode includes: forming a mixture of a polymer powder and an active material into a fiber; weaving the fiber into a woven film; and carbonizing the woven film.

Abstract: One aspect provides a pharmaceutical composition and a pharmaceutical combination formulation contains the same, the pharmaceutical composition containing as active ingredients: a proton pump inhibitor or a pharmaceutically acceptable salt thereof; and an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: A device is provided for performing a pressure test on a battery module. The device may include a module case in which battery cells are accommodated, a pressure plate installed in a middle portion of the module case in a width direction and configured to pressurize the battery cells toward the module case, a pressure driver configured to apply a pressure to the pressure plate, and a controller configured to control a pressure force and a pressure pattern with respect to the battery cells. The pressure plate may be configured to simulate expansion and contraction of the battery cells by repeatedly pressurizing and depressurizing the battery cells.

Abstract: A method of controlling a wireless power receiver can include transmitting, during a first determination phase, a foreign object detection status packet; before entering a first power transfer mode for receiving first power and before entering a second power transfer mode for receiving second power, receiving a determination result as to whether a foreign object is present determined based on the foreign object detection status packet; in response to determining that the foreign object is present based on the determination result, receiving the first power according to the first power transfer mode; and in response to determining that the foreign object is not present based on the determination result, receiving the second power according to the second power transfer mode.

Abstract: Provided are a composite formulation including sitagliptin and dapagliflozin and a method of preparing the same.

Abstract: Provided are a pharmaceutical composite formulation and a method of preparing the same, the pharmaceutical composite formulation including: a first layer containing, as an active ingredient, a proton pump inhibitor or a pharmaceutically acceptable salt thereof and a lubricant, and a second layer containing, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, and a mixture thereof.

Abstract: According to an aspect, provided are a composite tablet and a method of preparing the composite tablet, wherein the composite tablet may include a first layer including dry granules that include sitagliptin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and dapagliflozin or a pharmaceutically acceptable salt thereof, or a hydrate thereof, and a second layer including wet granules that include metformin or a pharmaceutically acceptable salt thereof and colloidal silicon dioxide.

Abstract: The present disclosure discloses a method for preparing a hybrid-type fluorine-based nonionic surfactant capable of producing a high purity material in a high yield. By preparing a hybrid-type fluorine-based nonionic surfactant according to the present disclosure, the surfactant is mass-produced in a high yield through controlling reaction conditions including a solvent.

Abstract: An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

Abstract: The present invention relates to a pharmaceutical preparation comprising a granule comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof, and a diluent. The pharmaceutical preparation has a high productivity of the preparation due to excellent tableting properties, friability, and mass uniformity. The pharmaceutical preparation has low generated amount of impurities and high stability.

Abstract: Disclosed are an acid-resistant pharmaceutical composition including tamsulosin hydrochloride, and a method of preparing the same. The pharmaceutical composition is formulated into tablets by preparing core beads including tamsulosin hydrochloride as an active ingredient, coating the core beads with an entering coating solution including a specific amount of plasticizer, adding a post mixture portion including a buffer to adjust density and a lubricant to the enteric-coated core beads, and performing tableting. The enteric coating layer is not broken during the tableting process. Thus, the acid resistance of the pharmaceutical composition is maintained. The pharmaceutical composition can be easily formulated into tablets, ensures good uniformity of dosage unit, lowers dissolution rate of tamsulosin hydrochloride, has good acid resistance, and is stable not to exhibit signification decomposition of tamsulosin hydrochloride.

Abstract: A semiconductor light emitting device includes a plurality of light emitting structures, an isolation layer covering side surfaces of the plurality of light emitting structures and insulating the plurality of light emitting structures from one another, a partition layer formed on the isolation layer, a first protective layer covering top surfaces of the plurality of light emitting structures and side walls of the partition layer, a reflective layer covering the first protective layer and disposed on the side walls of the partition layer, and a second protective layer covering the reflective layer.

Abstract: Provided is an oral pharmaceutical formulation including sustained-release pellets containing tamsulosin hydrochloride and a pharmaceutically acceptable additive, wherein the sustained-release pellets includes about 50 wt % to about 100 wt % of particles having a particle size of about 0.50 mm to about 0.85 mm, and less than about 15 wt % of particles having a particle size less than about 0.50 mm. The oral pharmaceutical formulation may have a reduced deviation in dissolution rate of tamsulosin hydrochloride and improved content uniformity among unit dosage forms, and have ensured quality due to high reproducibility of unit dosage forms.

Abstract: The present invention relates to a method for detecting a foreign material, and a device and system therefor.